Irit Gliko-Kabir has been with BioLineRx since June 2017, after spending ~11 years in different global clinical operation management positions within Teva Pharmaceuticals and the Innovative R&D Division of Teva Pharmaceutical Industries. Irit managed key phase 3 studies by Teva, two of which were registrational trials towards an innovative drug regulatory approval. At BioLineRx, Dr. Gliko-Kabir manages all clinical activities and managed the writing of all clinical sections in the dossier preparations for the submission and review of the New Drug Application for BioLineRx’s innovative drug, Aphexda®, which was approved by the FDA in 2023. Dr. Gliko-Kabir also managed the clinical team’s preparation for the FDA preapproval inspection. In addition to her clinical operations responsibilities, Irit leads data management activities in the company. Dr. Gliko-Kabir received her M.Sc. in Medicinal Chemistry and Ph.D. in Pharmacy, both from the Hebrew University School of Pharmacy in Jerusalem.